ArticleOphthalmology science2026
Differential Remodeling of the Macular Neovascular Network under Different Anti-VEGF Agents in Age-Related Macular Degeneration.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare treatment-induced changes in OCT B-scan and OCT angiography (OCTA)-derived characteristics of the macular neovascular (MNV) network among different anti-VEGF agents in neovascular age-related macular degeneration (nAMD). Design: Multicenter retrospective observational cohort study. Subjects: A total of 120 eyes from 102 patients with nAMD treated with ranibizumab 0.5 mg every 4 weeks (n = 30), aflibercept 2.0 mg every 4 weeks (n = 30), aflibercept 8.0 mg every 12 weeks (n = 30), or faricimab 6.0 mg every 8 weeks (n = 30) in a treat-and-extend regimen. Methods: Eyes with good-quality OCT B-scan and OCTA acquisitions at baseline and 1-year follow-up were included. OCT B-scan variables included pigment epithelium detachment (PED) height, PED homogeneity, and presence of intraretinal cystoid lesions and hyperreflective foci. OCT angiography variables included greatest linear diameter (GLD), MNV area, vessel density (VD), vessel length density (VLD), and VD index (VDI). Main Outcome Measures: Between-group differences in OCT B-scan and OCTA parameters at 1-year follow-up, adjusted for baseline values and clinical covariates using multivariable regression with cluster-robust standard errors. Results: Baseline characteristics were comparable across groups. Significant between-group differences were observed at 1 year for GLD ( Conclusions: Dual VEGF-A/angiopoietin-2 inhibition with faricimab induces greater anatomical remodeling of the MNV network compared with VEGF-A inhibition alone, with a distinct pattern characterized by preferential impact on larger-caliber vessels. These findings suggest that targeting the angiopoietin-2 pathway extends the morphological effects of anti-VEGF therapy beyond peripheral capillary pruning. Long-term studies are needed to determine whether deeper anatomical suppression translates into improved clinical outcomes or influences the trajectory of macular atrophy. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.